Journal of Integrative Medicine-Jim最新文献

{"title":"Blinding assessment in clinical trials of traditional Chinese medicine: Exploratory principles and protocol","authors":"Xiao-cong Wang ,&nbsp;Xiao-yu Liu ,&nbsp;Kang-le Shi ,&nbsp;Qing-gang Meng ,&nbsp;Yue-fan Yu ,&nbsp;Shi-yao Wang ,&nbsp;Juan Wang ,&nbsp;Chang Qu ,&nbsp;Cong Lei ,&nbsp;Xin-ping Yu","doi":"10.1016/j.joim.2023.10.003","DOIUrl":"10.1016/j.joim.2023.10.003","url":null,"abstract":"<div><p>As one of the key components of clinical trials<span>, blinding, if successfully implemented, can help to mitigate the risks of implementation bias and measurement bias, consequently improving the validity and reliability of the trial results. However, successful blinding in clinical trials of traditional Chinese medicine (TCM) is hard to achieve, and the evaluation of blinding success through blinding assessment lacks established guidelines. Taking into account the challenges associated with blinding in the TCM field, here we present a framework for assessing blinding. Further, this study proposes a blinding assessment protocol for TCM clinical trials, building upon the framework and the existing methods. An assessment report checklist and an approach for evaluating the assessment results are presented based on the proposed protocol. It is anticipated that these improvements to blinding assessment will generate greater awareness among researchers, facilitate the standardization of blinding, and augment the blinding effectiveness. The use of this blinding assessment may further advance the quality and precision of TCM clinical trials and improve the accuracy of the trial results. The blinding assessment protocol will undergo continued optimization and refinement, drawing upon expert consensus and experience derived from clinical trials.</span></p><p>Please cite this article as: Wang XC, Liu XY, Shi KL, Meng QG, Yu YF, Wang SY, Wang J, Qu C, Lei C, Yu XP. Blinding assessment in clinical trials of traditional Chinese medicine: Exploratory principles and protocol. <em>J Integr Med</em>. 2023; 21(6): 528–536.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 528-536"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92154762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroacupuncture for abdominal pain relief in patients with acute pancreatitis: A three-arm randomized controlled trial","authors":"Dong Kee Jang ,&nbsp;Jun Kyu Lee ,&nbsp;Chan Yung Jung ,&nbsp;Kyung Ho Kim ,&nbsp;Ha Ra Kang ,&nbsp;Yeon Sun Lee ,&nbsp;Jong Hwa Yoon ,&nbsp;Kwang Ro Joo ,&nbsp;Min Kyu Chae ,&nbsp;Yong Hyeon Baek ,&nbsp;Byung-Kwan Seo ,&nbsp;Sang Hyub Lee ,&nbsp;Chiyeon Lim","doi":"10.1016/j.joim.2023.10.004","DOIUrl":"10.1016/j.joim.2023.10.004","url":null,"abstract":"<div><h3>Background</h3><p>Electroacupuncture<span> (EA) may reduce the severity of acute pancreatitis (AP) and provide additional pain relief in patients<span> with chronic pancreatitis. However, the ability of EA to relieve pain in patients with AP has not been well documented.</span></span></p></div><div><h3>Objective</h3><p>This study was undertaken to compare the pain-relieving effects of EA and conventional treatment in patients with AP.</p></div><div><h3>Design, setting, participants and interventions</h3><p>This study was conducted using a randomized, controlled, three-arm, parallel-group and multi-center design. Patients diagnosed with AP were randomly and equally assigned to EA1, EA2 or control groups. All participants received conventional standard-of-care therapy for AP. Local EA alone was administered in EA1, and local plus distal EA was given in EA2. Local EA included two abdominal acupoints, while distal EA included twelve peripheral acupoints. EA groups underwent one session of EA daily for 4 days (days 1–4), or until pain was resolved or discharged.</p></div><div><h3>Main outcome measures</h3><p>The primary outcome measure was the change in the visual analogue scale (VAS; 0–100) pain score between baseline and day 5.</p></div><div><h3>Results</h3><p>Eighty-nine participants were randomized into EA1, EA2 and control groups, and 88 (EA1, 30; EA2, 29; control, 29) were included in the full-analysis set. VAS score change (median [interquartile range]) on day 5 was (12.3 ± 22.5) in the EA1 group, (10.3 ± 21.5) in the EA2 group, and (8.9 ± 15.2) in the control group. There were not significant differences in the change in VAS score among treatments (<em>P</em> = 0.983). However, time to food intake was significantly shorter in the EA group (EA1 + EA2) than in the control group (median 2.0 days <em>vs</em> 3.0 days), with a hazard ratio of 0.581 (<em>P</em> = 0.022; 95% CI, 0.366–0.924). No significant adverse events occurred.</p></div><div><h3>Conclusion</h3><p>EA treatment did not significantly reduce pain after 4 days of treatment in patients with AP-associated abdominal pain but significantly reduced time to first food intake.</p><p><em>Trial registration:</em> ClinicalTrials.gov identifier NCT03173222.</p><p><span>Please cite this article as: Jang DK, Lee JK, Jung CY, Kim KH, Kang HR, Lee YS, Yoon JH, Joo KR, Chae MK, Baek YH, Seo BK, Lee SH, Lim C. Electroacupuncture for abdominal pain relief in patients with acute pancreatitis: A three-arm randomized controlled trial. </span><em>J Integr Med</em>. 2023; 21(6): 537–542.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 537-542"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135325450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role and advantage of traditional Chinese medicine in the prevention and treatment of COVID-19","authors":"Ming Huang ,&nbsp;Yao-yuan Liu ,&nbsp;Ke Xiong ,&nbsp;Feng-wen Yang ,&nbsp;Xin-yao Jin ,&nbsp;Zhao-qi Wang ,&nbsp;Jun-hua Zhang ,&nbsp;Bo-li Zhang","doi":"10.1016/j.joim.2023.08.003","DOIUrl":"10.1016/j.joim.2023.08.003","url":null,"abstract":"<div><p><span>The global coronavirus disease 2019 (COVID-19) pandemic has had a massive impact on global social and economic development and </span>human health<span>. By combining traditional Chinese medicine<span><span><span> (TCM) with modern medicine, the Chinese government has protected public health by supporting all phases of COVID-19 prevention and treatment<span>, including community prevention, clinical treatment, control of disease progression, and promotion of recovery. Modern medicine focuses on </span></span>viruses, while TCM focuses on differential diagnosis of patterns associated with viral infection of the body and recommends the use of </span>TCM decoctions for differential treatment. This differential diagnosis and treatment approach, with its profoundly empirical nature and holistic view, endows TCM with an accessibility advantage and high application value for dealing with COVID-19. Here, we summarize the advantage of and evidence for TCM use in COVID-19 prevention and treatment to draw attention to the scientific value and accessibility advantage of TCM and to promote the use of TCM in response to public health emergencies.</span></span></p><p>Please cite this article as: Huang M, Liu YY, Xiong K, Yang FW, Jin XY, Wang ZQ, Zhang JH, Zhang BL. The role and advantage of traditional Chinese medicine in the prevention and treatment of COVID-19. <em>J Integr Med</em>. 2023; 21(5): 407–412.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 407-412"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis","authors":"Chong-yang Sun ,&nbsp;Zhi-yi Xiong ,&nbsp;Cheng-yi Sun ,&nbsp;Pei-hong Ma ,&nbsp;Xiao-yu Liu ,&nbsp;Chi-yun Sun ,&nbsp;Ze-yin Xin ,&nbsp;Bao-yan Liu ,&nbsp;Cun-zhi Liu ,&nbsp;Shi-yan Yan","doi":"10.1016/j.joim.2023.08.005","DOIUrl":"10.1016/j.joim.2023.08.005","url":null,"abstract":"<div><h3>Background</h3><p>The placebo response<span><span> of sham acupuncture </span>in patients<span> with primary dysmenorrhea is a substantial factor associated with analgesia. However, the magnitude of the placebo response is unclear.</span></span></p></div><div><h3>Objective</h3><p>This meta-analysis assessed the effects of sham acupuncture in patients with primary dysmenorrhea and the factors contributing to these effects.</p></div><div><h3>Search strategy</h3><p>PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were searched from inception up to August 20, 2022.</p></div><div><h3>Inclusion criteria</h3><p>Randomized controlled trials (RCTs) using sham acupuncture as a control for female patients of reproductive age with primary dysmenorrhea were included.</p></div><div><h3>Data extraction and analysis</h3><p>Pain intensity, retrospective symptom scale, and health-related quality of life were outcome measures used in these trials. Placebo response was defined as the change in the outcome of interest from baseline to endpoint. We used standardized mean difference (SMD) to estimate the effect size of the placebo response.</p></div><div><h3>Results</h3><p>Thirteen RCTs were included. The pooled placebo response size for pain intensity was the largest (SMD = −0.99; 95% confidence interval [CI], −1.31 to −0.68), followed by the retrospective symptom scale (Total frequency rating score: SMD = −0.20; 95% CI, −0.80 to −0.39. Average severity score: SMD = −0.35; 95% CI, −0.90 to −0.20) and physical component of SF-36 (SMD = 0.27; 95% CI, −0.17 to 0.72). Studies using blunt-tip needles, single-center trials, studies with a low risk of bias, studies in which patients had a longer disease course, studies in which clinicians had &lt; 5 years of experience, and trials conducted outside Asia were more likely to have a lower placebo response.</p></div><div><h3>Conclusion</h3><p>Strong placebo response and some relative factors were found in patients with primary dysmenorrhea.</p><p><em>PROSPERO registration number:</em> CRD42022304215.<br></p><p>Please cite this article as: Sun CY, Xiong ZY, Sun CY, Ma PH, Liu XY, Sun CY, Xin ZY, Liu BY, Liu CZ, Yan SY. Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis. <em>J Integr Med</em>. 2023; 21(5): 455–463.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 455-463"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives","authors":"Mei Zhang ,&nbsp;Rui Zheng ,&nbsp;Wen-jing Liu ,&nbsp;Jun-ling Hou ,&nbsp;Yu-lei Yang ,&nbsp;Hong-cai Shang","doi":"10.1016/j.joim.2023.08.004","DOIUrl":"10.1016/j.joim.2023.08.004","url":null,"abstract":"<div><p><span><span><span>Severe pneumonia is one of the most common infectious diseases and the leading cause of sepsis and septic shock<span>. Preventing infection, balancing the patient’s immune status, and anti-coagulation therapy are all important elements in the treatment of severe pneumonia. As multi-target agents, Xuebijing injection (XBJ) has shown unique advantages in targeting complex conditions and saving the lives of patients with severe pneumonia. This review outlines progress in the understanding of XBJ’s anti-inflammatory, </span></span>endotoxin<span> antagonism, and anticoagulation effects. From the hundreds of publications released over the past few years, the key results from representative clinical studies of XBJ in the treatment of severe pneumonia were selected and summarized. XBJ was observed to effectively suppress the release of pro-inflammatory cytokines, counter the effects of endotoxin, and assert an anticoagulation effect in most </span></span>clinical trials<span>, which are consistent with experimental studies. Collectively, this evidence suggests that XBJ could play an important and expanding role in clinical medicine, especially for sepsis, septic shock and severe pneumonia.</span></span><br></p><p>Please cite this article as: Zhang M, Zheng R, Liu WJ, Hou JL, Yang YL, Shang HC. Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives. <em>J Integr Med</em>. 2023; 21(5): 413–422.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 413-422"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10304085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroacupuncture alleviates postoperative pain through inhibiting neuroinflammation via stimulator of interferon genes/type-1 interferon pathway","authors":"Yuan-yuan Ding ,&nbsp;Feng Xu ,&nbsp;Ya-feng Wang,&nbsp;Lin-lin Han,&nbsp;Shi-qian Huang,&nbsp;Shuai Zhao,&nbsp;Lu-lin Ma,&nbsp;Tian-hao Zhang,&nbsp;Wen-jing Zhao,&nbsp;Xiang-dong Chen","doi":"10.1016/j.joim.2023.07.001","DOIUrl":"10.1016/j.joim.2023.07.001","url":null,"abstract":"<div><h3>Objective</h3><p><span><span>This work explores the impact of electroacupuncture (EA) on acute </span>postoperative pain (APP) and the role of stimulator of </span>interferon<span><span> genes/type-1 interferon (STING/IFN-1) signaling pathway modulation in the </span>analgesic effect of EA in APP rats.</span></p></div><div><h3>Methods</h3><p>The APP rat model was initiated through abdominal surgery<span><span> and the animals received two 30 min sessions of EA at bilateral ST36 (Zusanli) and SP6 (Sanyinjiao) acupoints. Mechanical, thermal and cold sensitivity tests were performed to measure the pain threshold, and electroencephalograms were recorded in the primary somatosensory cortex to identify the effects of EA </span>treatment<span> on APP. Western blotting<span> and immunofluorescence<span> were used to examine the expression and distribution of proteins in the STING/IFN-1 pathway as well as neuroinflammation. A STING inhibitor (C-176) was administered intrathecally to verify its role in EA.</span></span></span></span></p></div><div><h3>Results</h3><p><span>APP rats displayed mechanical and thermal hypersensitivities compared to the control group (</span><em>P</em> &lt; 0.05). APP significantly reduced the amplitude of θ, α and γ oscillations compared to their baseline values (<em>P</em> &lt; 0.05). Interestingly, expression levels of proteins in the STING/IFN-1 pathway were downregulated after inducing APP (<em>P</em><span> &lt; 0.05). Further, APP increased pro-inflammatory factors, including interleukin-6, tumor necrosis factor-α and inducible nitric oxide synthase, and downregulated anti-inflammatory factors, including interleukin-10 and arginase-1 (</span><em>P</em> &lt; 0.05). EA effectively attenuated APP-induced painful hypersensitivities (<em>P</em> &lt; 0.05) and restored the θ, α and γ power in APP rats (<em>P</em> &lt; 0.05). Meanwhile, EA distinctly activated the STING/IFN-1 pathway and mitigated the neuroinflammatory response (<em>P</em><span><span> &lt; 0.05). Furthermore, STING/IFN-1 was predominantly expressed in isolectin-B4- or calcitonin-gene-related-peptide-labeled dorsal root<span> ganglion neurons and superficial laminae of the spinal dorsal horn. Inhibition of the STING/IFN-1 pathway by </span></span>intrathecal injection<span> of C-176 weakened the analgesic and anti-inflammatory effects of EA on APP (</span></span><em>P</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>EA can generate robust analgesic and anti-inflammatory effects on APP, and these effects may be linked to activating the STING/IFN-1 pathway, suggesting that STING/IFN-1 may be a target for relieving APP.</p><p>Please cite this article as: Ding YY, Xu F, Wang YF, Han LL, Huang SQ, Zhao S, Ma LL, Zhang TH, Zhao WJ, Chen XD. Electroacupuncture alleviates postoperative pain through inhibiting neuroinflammation via stimulator of interferon genes/type-1 interferon pathway. <em>J Integr Med</em>. 2023; 21(5): 496–508.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 496-508"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10649355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baicalin, silver titanate, Bletilla striata polysaccharide and carboxymethyl chitosan in a porous sponge dressing for burn wound healing","authors":"Yan-rong Gong ,&nbsp;Cheng Zhang ,&nbsp;Xing Xiang ,&nbsp;Zhi-bo Wang ,&nbsp;Yu-qing Wang ,&nbsp;Yong-hua Su ,&nbsp;Hui-qing Zhang","doi":"10.1016/j.joim.2023.07.002","DOIUrl":"10.1016/j.joim.2023.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>This study tests the efficacy of <em>Bletilla striata</em><span><span> polysaccharide<span> (BSP), carboxymethyl chitosan (CMC), baicalin (BA) and silver titanate (ST) in a </span></span>wound dressings<span> to fight infection, promote healing and provide superior biocompatibility.</span></span></p></div><div><h3>Methods</h3><p><span>The antibacterial activity of BA and ST was evaluated </span><em>in vitro</em> using the inhibition zone method. BA/ST/BSP/CMC porous sponge dressings were prepared and characterized. The biocompatibility of BA/ST/BSP/CMC was assessed using the cell counting kit-8 assay. The therapeutic effect of BA/ST/BSP/CMC was further investigated using the dorsal skin burn model in Sprague-Dawley rats.</p></div><div><h3>Results</h3><p>The wound dressing had good antibacterial activity against <em>Escherichia coli</em> and <span><em>Staphylococcus aureus</em></span><span> through BA and ST, while the combination of BSP and CMC played an important role in promoting wound healing. The BA/ST/BSP/CMC porous sponge dressings were prepared using a freeze-drying method with the concentrations of BA and ST at 20 and 0.83 mg/mL, respectively, and the optimal ratio of 5% BSP to 4% CMC was 1:3. The average porosity, water absorption and air permeability of BA/ST/BSP/CMC porous sponge dressings were measured to be 90.43%, 746.1% and 66.60%, respectively. After treatment<span> for 3 and 7 days, the healing rates of the BA/ST/BSP/CMC group and BA/BSP/CMC group were significantly higher than those of the normal saline (NS) group and silver sulfadiazine (SSD) group (</span></span><em>P</em> &lt; 0.05). Interleukin-1β expression in the BA/ST/BSP/CMC group at 1 and 3 days was significantly lower than that in the other three groups (<em>P</em> &lt; 0.05). After being treated for 3 days, vascular endothelial growth factor expression in the BA/BSP/CMC group and BA/ST/BSP/CMC group was significantly higher than that in the NS group and SSD group (<em>P</em> &lt; 0.05). Inspection of histological sections showed that the BA/ST/BSP/CMC group and BA/BSP/CMC group began to develop scabbing and peeling of damaged skin after 3 days of treatment, indicating accelerated healing relative to the NS group and SSD group.</p></div><div><h3>Conclusion</h3><p>The optimized concentration of BA/ST/BSP/CMC dressing was as follows: 6 mg BSP, 14.4 mg CMC, 0.5 mg ST and 12 mg BA. The BA/ST/BSP/CMC dressing, containing antibacterial constituents, was non-cytotoxic and effective in accelerating the healing of burn wounds, making it a promising candidate for wound healing.</p><p>Please cite this article as: Gong YR, Zhang C, Xiang X, Wang ZB, Wang YQ, Su YH, Zhang HQ. Baicalin, silver titanate, <em>Bletilla striata</em> polysaccharide and carboxymethyl chitosan in a porous sponge dressing for burn wound healing. <em>J Integr Med</em>. 2023; 21(5): 487–495.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 487-495"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jiedu Recipe, a compound Chinese herbal medicine, inhibits cancer stemness in hepatocellular carcinoma via Wnt/β-catenin pathway under hypoxia","authors":"Bing-jie Guo ,&nbsp;Yi Ruan ,&nbsp;Ya-jing Wang ,&nbsp;Chu-lan Xiao ,&nbsp;Zhi-peng Zhong ,&nbsp;Bin-bin Cheng ,&nbsp;Juan Du ,&nbsp;Bai Li ,&nbsp;Wei Gu ,&nbsp;Zi-fei Yin","doi":"10.1016/j.joim.2023.06.008","DOIUrl":"10.1016/j.joim.2023.06.008","url":null,"abstract":"<div><h3>Objective</h3><p><span>Jiedu Recipe (JR), a Chinese herbal remedy, has been shown to prolong overall survival time and decrease recurrence and metastasis rates </span>in patients<span> with hepatocellular carcinoma (HCC). This work investigated the mechanism of JR in HCC treatment.</span></p></div><div><h3>Methods</h3><p><span>The chemical constituents of JR were detected using liquid chromatography-mass spectrometry. The potential anti-HCC mechanism of JR was screened using network pharmacology and messenger ribonucleic acid (mRNA) microarray chip assay, followed by experimental validation in human HCC cells (SMMC-7721 and Huh7) </span><em>in vitro</em> and a nude mouse subcutaneous transplantation model of HCC <em>in vivo</em><span>. HCC cell characteristics of proliferation, migration and invasion under hypoxic setting were investigated using thiazolyl blue tetrazolium<span><span> bromide, wound healing and Transwell assays, respectively. Image-iT™ Hypoxia Reagent was added to reveal hypoxic conditions. Stem cell sphere formation assay was used to detect the stemness. Epithelial-mesenchymal transition (EMT) markers like E-cadherin, </span>vimentin<span><span> and α-smooth muscle actin, and pluripotent transcription factors including nanog homeobox, octamer-binding transcription factor 4, and sex-determining region Y box protein 2 were analyzed using </span>Western blotting and real-time polymerase chain reaction. Western blot was performed to ascertain the anti-HCC effect of JR under hypoxia involving the Wnt/β-catenin pathway.</span></span></span></p></div><div><h3>Results</h3><p>According to network pharmacology and mRNA microarray chip analysis, JR may potentially act on hypoxia and inhibit the Wnt/β-catenin pathway. <em>In vitro</em> and <em>in vivo</em> experiments showed that JR significantly decreased hypoxia, and suppressed HCC cell features of proliferation, migration and invasion; furthermore, the hypoxia-induced increases in EMT and stemness marker expression in HCC cells were inhibited by JR. Results based on the co-administration of JR and an agonist (LiCl) or inhibitor (IWR-1-endo) verified that JR suppressed HCC cancer stem-like properties under hypoxia by blocking the Wnt/β-catenin pathway.</p></div><div><h3>Conclusion</h3><p>JR exerts potent anti-HCC effects by inhibiting cancer stemness via abating the Wnt/β-catenin pathway under hypoxic conditions.</p><p><span>Please cite this article as: Guo BJ, Ruan Y, Wang YJ, Xiao CL, Zhong ZP, Cheng BB, Du J, Li B, Gu W, Yin ZF. Jiedu Recipe, a compound Chinese herbal medicine, inhibits cancer stemness in hepatocellular carcinoma via Wnt/β-catenin pathway under hypoxia. </span><em>J Integr Med</em>. 2023; 21(5): 474–486.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 474-486"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of hyperbaric oxygen therapy on human psychomotor performance: A review","authors":"Dorota Olex-Zarychta","doi":"10.1016/j.joim.2023.08.006","DOIUrl":"10.1016/j.joim.2023.08.006","url":null,"abstract":"<div><p><span>Psychomotor performance<span> is the coordination of a sensory or ideational (cognitive) process and a motor activity. All sensorimotor processes involved in planning and execution of voluntary movements need oxygen supply and seem to be significantly disrupted in states of hypoxia<span>. Hyperbaric oxygen therapy<span> has become a widely used treatment<span> in routine medicine and sport medicine due to its beneficial effects on different aspects of </span></span></span></span></span>human physiology<span> and performance. This paper presents state-of-the-art data on the effects of hyperbaric oxygen therapy on different aspects of human psychomotor function<span><span>. The therapy’s influence on musculoskeletal properties and motor abilities as well as the effects of hyperbaric oxygenation on cognitive, myocardial and pulmonary functions are presented. In this review the molecular and physiological processes related to human psychomotor performance in response to hyperbaric oxygen are discussed to contribute to this fast-growing field of research in </span>integrative medicine.</span></span></p><p>Please cite this article as: Olex-Zarychta D. Effects of hyperbaric oxygen therapy on human psychomotor performance: A review. <em>J Integr Med</em>. 2023; 21(5): 430–440.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 430-440"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10357355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical evidence of three traditional Chinese medicine drugs and three herbal formulas for COVID-19: A systematic review and meta-analysis of the Chinese population","authors":"Liang-zhen You ,&nbsp;Qian-qian Dai ,&nbsp;Xiao-ying Zhong ,&nbsp;Dong-dong Yu ,&nbsp;He-rong Cui ,&nbsp;Yi-fan Kong ,&nbsp;Meng-zhu Zhao ,&nbsp;Xin-yi Zhang ,&nbsp;Qian-qian Xu ,&nbsp;Zhi-yue Guan ,&nbsp;Xu-xu Wei ,&nbsp;Xue-cheng Zhang ,&nbsp;Song-jie Han ,&nbsp;Wen-jing Liu ,&nbsp;Zhao Chen ,&nbsp;Xiao-yu Zhang ,&nbsp;Chen Zhao ,&nbsp;Ying-hui Jin ,&nbsp;Hong-cai Shang","doi":"10.1016/j.joim.2023.08.001","DOIUrl":"10.1016/j.joim.2023.08.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;The coronavirus disease 2019 (COVID-19) continues to spread worldwide. Integrated Chinese and Western medicine have had some successes in treating COVID-19.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;&lt;span&gt;This study aims to evaluate the efficacy and safety of three traditional Chinese medicine &lt;/span&gt;drugs&lt;span&gt; and three herbal formulas (3-drugs-3-formulas) in patients with COVID-19.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Search strategy&lt;/h3&gt;&lt;p&gt;Relevant studies were identified from 12 electronic databases searched from their establishment to April 7, 2022.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Inclusion criteria&lt;/h3&gt;&lt;p&gt;Randomized controlled trials&lt;span&gt; (RCTs), non-RCTs and cohort studies&lt;span&gt; that evaluated the effects of 3-drugs-3-formulas for COVID-19. The treatment group was treated with one of the 3-drugs-3-formulas plus conventional treatment. The control group was treated with conventional treatment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Data extraction and analysis&lt;/h3&gt;&lt;p&gt;Two evaluators screened and selected literature independently, then extracted basic information and assessed risk of bias. The treatment outcome measures were duration of main symptoms, hospitalization time, aggravation rate and mortality. RevMan 5.4 was used to analyze the pooled results reported as mean difference (MD) with 95% confidence interval (CI) for continuous data and risk ratio (RR) with 95% CI for dichotomous data.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Forty-one studies with a total of 13,260 participants were identified. Our analysis suggests that compared with conventional treatment, the combination of 3-drugs-3-formulas might shorten duration of fever (MD = –1.39; 95% CI: –2.19 to –0.59; &lt;em&gt;P&lt;/em&gt; &lt; 0.05), cough (MD = –1.57; 95% CI: –2.16 to –0.98; &lt;em&gt;P&lt;/em&gt; &lt; 0.05) and fatigue (MD = –1.36; 95% CI: –2.21 to –0.51; &lt;em&gt;P&lt;/em&gt; &lt; 0.05), decrease length of hospital stay (MD = –2.62; 95% CI –3.52 to –1.72; &lt;em&gt;P&lt;/em&gt;&lt;span&gt; &lt; 0.05), the time for nucleic acid conversion (MD = –2.92; 95% CI: –4.26 to –1.59; &lt;/span&gt;&lt;em&gt;P&lt;/em&gt; &lt; 0.05), aggravation rate (RR = 0.49; 95% CI: 0.38 to 0.64; &lt;em&gt;P&lt;/em&gt; &lt; 0.05) and mortality (RR = 0.34; 95% CI: 0.19 to 0.62; &lt;em&gt;P&lt;/em&gt;&lt;span&gt; &lt; 0.05), and increase the recovery rate of chest computerized tomography manifestations (RR = 1.22; 95% CI: 1.14 to 1.3; &lt;/span&gt;&lt;em&gt;P&lt;/em&gt; &lt; 0.05) and total effectiveness (RR = 1.24; 95% CI: 1.09 to 1.42; &lt;em&gt;P&lt;/em&gt; &lt; 0.05).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;The 3-drugs-3-formulas can play an active role in treating all stages of COVID-19. No severe adverse events related to 3-drugs-3-formulas were observed. Hence, 3-drugs-3-formulas combined with conventional therapies have effective therapeutic value for COVID-19 patients. Further long-term high-quality studies are essential to demonstrate the clinical benefits of each formula.&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;Please cite this article as: You LZ, Dai QQ, Zhong XY, Yu DD, Cui HR, Kong YF, Zhao MZ, Zhang XY, Xu QQ, Guan ZY, Wei XX, Zhang XC, Han SJ, Liu WJ, Che","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 441-454"},"PeriodicalIF":4.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}